Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | LsmAD domain-containing protein | 0.002 | 0.0794 | 0.5 |
Chlamydia trachomatis | outer membrane protein PmpC | 0.0054 | 0.4571 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0037 | 0.2656 | 0.2091 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.0794 | 0.0086 |
Chlamydia trachomatis | outer membrane protein PmpF | 0.0054 | 0.4571 | 0.5 |
Brugia malayi | Pax transcription factor protein 2 | 0.0074 | 0.6823 | 0.6823 |
Brugia malayi | sulfakinin receptor protein | 0.0102 | 1 | 1 |
Loa Loa (eye worm) | pax transcription factor protein 2 | 0.0074 | 0.6823 | 0.6579 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.002 | 0.0794 | 0.5 |
Chlamydia trachomatis | outer membrane protein PmpD | 0.0054 | 0.4571 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.002 | 0.0794 | 0.5 |
Brugia malayi | hypothetical protein | 0.002 | 0.0794 | 0.0794 |
Chlamydia trachomatis | outer membrane protein PmpB | 0.0054 | 0.4571 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0037 | 0.2656 | 0.2091 |
Onchocerca volvulus | 0.0074 | 0.6823 | 0.5 | |
Plasmodium vivax | ataxin-2 like protein, putative | 0.002 | 0.0794 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.002 | 0.0794 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.002 | 0.0794 | 0.5 |
Brugia malayi | Angiotensin-converting enzyme family protein | 0.0019 | 0.0715 | 0.0715 |
Brugia malayi | MH2 domain containing protein | 0.0037 | 0.2656 | 0.2656 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.002 | 0.0794 | 0.5 |
Chlamydia trachomatis | outer membrane protein PmpE | 0.0054 | 0.4571 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0102 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.002 | 0.0794 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.6234 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.